Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D4CY
|
|||
| Former ID |
DAP001200
|
|||
| Drug Name |
Sulfapyridine
|
|||
| Synonyms |
Adiplon; Coccoclase; Dagenan; Eubasin; Eubasinum; Haptocil; Piridazol; Plurazol; Pyriamid; Pyridazol; Relbapiridina; Ronin;Septipulmon; Solfapiridina; Streptosilpyridine; Sulfapiridina; Sulfapyridinum; Sulfidin; Sulfidine; Sulphapyridin; Sulphapyridine; Thioseptal; Trianon; Solfapiridina [DCIT]; M and B 693; A-499; ALBB-006215; M + B 693; M&B 693; M+B 693; Sulfapiridina [INN-Spanish]; Sulfapyridine (TN); Sulfapyridinum [INN-Latin]; AO-801/41077453; N(1)-Pyridylsulfanilamide; N(sup1)-Pyridylsulfanilamide; N-2-Pyridylsulfanilamide; N1-2-Pyridylsulfanilamide; Sulfapyridine (USP/INN); Sulfapyridine [USAN:INN:BAN]; N'-2-Pyridylsulfanilide; N(1)-2-Pyridylsulfanilamide; N(sup 1)-2-Pyridylsulfanilamide; N1-(Pyridin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyridyl-(8CI); 2-(4-Aminobenzenesulfonamido)pyridine; 2-(p-Aminobenzenesulphonamido)pyridine; 2-Sulfanilamidopyridin; 2-Sulfanilamidopyridin [German]; 2-Sulfanilamidopyridine; 2-Sulfanilyl aminopyridine; 2-Sulfanilylaminopyridine; 2-Sulfapyridine; 4-(2-Pyridinylsulfonyl)aniline; 4-AMINO-N-2-PYRIDINYLBENZENESULFONAMIDE; 4-Amino-N,2-pyridinylbenzenesulfonamide; 4-Amino-N-2-pyridinyl-benzenesulfonamide; 4-Amino-N-[2-pyridyl]benzene sulfonamide; 4-[(2-Pyridylamino)sulfonyl]aniline; 4-amino-N-(pyridin-2-yl)benzenesulfonamide; 4-amino-N-pyridin-2-yl-benzenesulfonamide; 4-amino-N-pyridin-2-ylbenzenesulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Dermatitis herpetiformis [ICD-11: EB44; ICD-10: L13.0; ICD-9: 694] | Approved | [1], [2] | |
| Therapeutic Class |
Dermatologic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H11N3O2S
|
|||
| Canonical SMILES |
C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N
|
|||
| InChI |
1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)
|
|||
| InChIKey |
GECHUMIMRBOMGK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 144-83-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
70988, 96525, 603199, 855656, 866442, 5631195, 7820105, 7849492, 7980704, 8149538, 8153278, 10321924, 10508192, 11112302, 11335391, 11360630, 11363890, 11366452, 11369014, 11372864, 11373890, 11377176, 11461602, 11466790, 11467910, 11485181, 11486479, 11489139, 11491588, 11492161, 11494810, 15221159, 17140599, 24899692, 26611930, 26679786, 26746948, 29224390, 46506991, 47291019, 47365061, 47365062, 47515199, 47662144, 47736350, 48110333, 48110334, 48424128, 49698734, 49855022
|
|||
| ChEBI ID |
CHEBI:132842
|
|||
| SuperDrug ATC ID |
J01EB04
|
|||
| SuperDrug CAS ID |
cas=000144832
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Metabolic Reaction | Acetylation | |||
| Resulting Metabolite | N-acetyl-5-aminosalicylic acid | |||
| Description | Sulfapyridine can be metabolized to N-acetyl-5-aminosalicylic acid by gut microbiota through acetylation. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Dihydropteroate synthetase (Bact folP) | Target Info | Inhibitor | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 000159. | |||
| REF 3 | Human gut microbiota plays a role in the metabolism of drugs. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Sep;160(3):317-26. | |||
| REF 4 | A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.